Hikal LtdQ1 FY27
Hikal Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹204P/E: 62.7Market Cap: ₹2.7K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
No
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- →FY27 full-year growth expected to be approximately 14% to 16%, driven by strong pharma growth and marginal crop growth.
- →Pharma business projected to grow at 18% to 19% CAGR going forward, potentially faster with pending approvals and NCE filings.
- →Animal Health business targeted to reach Rs. 400 crores revenue by FY30, with sustained strong customer demand and portfolio expansion.
- →Personal Care segment is a new growth driver, expected to cross Rs. 200 crores revenue in the next three years, with EBITDA margins over 20%.
- →Crop Protection business anticipates marginal, mid to high single-digit growth due to subdued pricing and demand pressures.
- →Pharma CDMO volumes expected to improve as deferred customer orders are executed in the second half of FY27.
- →Post U.S. FDA clearance, revenue ramp-up in pharma anticipated with better margins.
Margin guidance
Category 1- →Hikal expects a top-line CAGR of 15%-16% annually going forward, driven by strong growth in pharma (18%-19% CAGR) and marginal growth in crop.
- →EBITDA growth is projected at 25%-30% for FY27, with margins set to improve significantly from FY28 as FDA remediation costs cease.
- →The Animal Health business is targeted to reach Rs. 400 crores revenue by FY30 with EBITDA margins above 20%.
- →Personal Care segment aims to cross Rs. 200 crores revenues within three years, with EBITDA margins over 20%.
- →Pharma business recovery is anticipated post-U.S. FDA clearance, accelerating revenue growth and margin expansion.
- →Expected operating leverage gains as fixed costs stabilize and remediation expenses reduce.
- →Overall, FY28 is projected to be substantially better than FY27 and FY26, with strong profit and EPS growth driven by volume ramp-up and improved margins.
Fundraise plans
No- →No new fundraising through debt or equity is mentioned in the transcript.
- →Growth has been largely financed through internal accruals as of June 30, 2026.
- →The company has reduced its net debt from approximately Rs. 815 crores in FY24 to Rs. 685 crores by end of FY26.
- →Debt-to-equity ratio stands at 0.53 as of Q1 FY27, indicating a stable leverage position.
- →Capital expenditure of Rs. 45 crores in the quarter focused on de-bottlenecking, regulatory upgrades, and new capacities is funded internally.
- →The company emphasizes targeted capital allocation prioritizing high ROI projects aligned with long-term growth, without mention of new external funding sources.
Order book
- →The company has several contracts in process, with 2-3 new contracts expected post U.S. FDA clearance.
- →Customer confidence remains strong; no contracts or customers have been lost in the last year despite FDA issues.
- →Multiple NCE (New Chemical Entity) campaigns and molecule programs are underway, reflecting a healthy order pipeline.
- →Animal Health business has long-term contracts with global innovators and repeat campaign orders.
- →Pharma CDMO business is building momentum with expanding customer engagement across North America, Europe, Japan, and emerging markets.
- →Discussions on strategic partnerships with Japanese companies are progressing well.
- →Pipeline includes around 8-9 molecules at various development stages toward commercialization.
- →The company is confident of accelerated revenue growth once FDA remediation is completed, with a stepwise recovery envisaged.
- →Overall visibility in orders is improving, with gradual normalization of customer ordering patterns and trade cycles.
Capex plans
Yes- →Rs. 45 crores capex in Q1 FY27: focused on de-bottlenecking, regulatory upgrades, and building new capacities.
- →Over last 4 years, approx. Rs. 900 crores invested in capex: Rs. 300 crores for maintenance CAPEX (~Rs. 75 crores/year across 6 sites).
- →Rs. 600 crores invested in growth CAPEX:
- → - Rs. 300 crores towards agrochemical manufacturing plant (part-impaired, now being retooled to reduce timelines by 12 months for Pharma/Animal Health portfolio).
- → - Rs. 150 crores in dedicated Animal Health manufacturing site (validations completed, revenues started).
- → - Rs. 100 crores in multipurpose manufacturing facility in Bangalore (already generating revenues).
- →New cGMP pilot plants commissioned improving R&D capabilities.
- →Commissioned dedicated multi-purpose manufacturing line at Panoli for Personal Care segment.
- →Ongoing investments aimed at flexible manufacturing capacities supporting Pharma, Animal Health, and Crop businesses.
- →Strategic partnerships discussions underway with Japanese companies to strengthen Animal Health segment.
Track Hikal Ltd — get its next earnings analysis in your feed
Margin guidance
Category 1- →Hikal expects a top-line CAGR of 15%-16% annually going forward, driven by strong growth in pharma (18%-19% CAGR) and marginal growth in crop.
- →EBITDA growth is projected at 25%-30% for FY27, with margins set to improve significantly from FY28 as FDA remediation costs cease.
- →The Animal Health business is targeted to reach Rs. 400 crores revenue by FY30 with EBITDA margins above 20%.
- →Personal Care segment aims to cross Rs. 200 crores revenues within three years, with EBITDA margins over 20%.
- →Pharma business recovery is anticipated post-U.S. FDA clearance, accelerating revenue growth and margin expansion.
- →Expected operating leverage gains as fixed costs stabilize and remediation expenses reduce.
- →Overall, FY28 is projected to be substantially better than FY27 and FY26, with strong profit and EPS growth driven by volume ramp-up and improved margins.
Order book
- →The company has several contracts in process, with 2-3 new contracts expected post U.S. FDA clearance.
- →Customer confidence remains strong; no contracts or customers have been lost in the last year despite FDA issues.
- →Multiple NCE (New Chemical Entity) campaigns and molecule programs are underway, reflecting a healthy order pipeline.
- →Animal Health business has long-term contracts with global innovators and repeat campaign orders.
- →Pharma CDMO business is building momentum with expanding customer engagement across North America, Europe, Japan, and emerging markets.
- →Discussions on strategic partnerships with Japanese companies are progressing well.
- →Pipeline includes around 8-9 molecules at various development stages toward commercialization.
- →The company is confident of accelerated revenue growth once FDA remediation is completed, with a stepwise recovery envisaged.
- →Overall visibility in orders is improving, with gradual normalization of customer ordering patterns and trade cycles.
How does Hikal Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Hikal Ltd
Rev 3Mar 1
See full Pharmaceuticals & Biotechnology sector rankings
How does Hikal Ltd rank in Pharmaceuticals & Biotechnology?
Compare Hikal Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.